$242 Million is the total value of SILVERARC CAPITAL MANAGEMENT, LLC's 72 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ETNB | New | 89bio Incequities | $6,674,014 | – | 438,215 | +100.0% | 2.76% | – |
| VKTX | New | Viking Therapeutics Incequities | $6,327,000 | – | 380,000 | +100.0% | 2.61% | – |
| KPTI | New | Karyopharm Therapeutics Incequities | $5,996,147 | – | 1,541,426 | +100.0% | 2.48% | – |
| KALV | New | KalVista Pharmaceuticals Incequities | $5,687,056 | – | 723,544 | +100.0% | 2.35% | – |
| PLRX | New | Pliant Therapeutics, Inccall | $5,309,360 | – | 199,600 | +100.0% | 2.19% | – |
| ACRS | New | Aclaris Therapeutics, Inccall | $5,269,826 | – | 651,400 | +100.0% | 2.18% | – |
| REGN | New | Regeneron Pharmaceuticals Incequities | $4,108,350 | – | 5,000 | +100.0% | 1.70% | – |
| ETNB | New | 89bio, Inccall | $3,046,000 | – | 200,000 | +100.0% | 1.26% | – |
| MIRM | New | Mirum Pharmaceuticals Incequities | $2,544,655 | – | 105,939 | +100.0% | 1.05% | – |
| INCY | New | Incyte Corpequities | $2,452,699 | – | 33,938 | +100.0% | 1.01% | – |
| PTGX | New | Protagonist Therapeutics Incequities | $2,426,178 | – | 105,486 | +100.0% | 1.00% | – |
| New | Ventyx Biosciences Incequities | $2,345,000 | – | 70,000 | +100.0% | 0.97% | – | |
| New | MoonLake Immunotherapeuticsequities | $2,261,993 | – | 105,750 | +100.0% | 0.93% | – | |
| PHAT | New | Phathom Pharmaceuticals Incequities | $1,428,000 | – | 200,000 | +100.0% | 0.59% | – |
| SRPT | New | Sarepta Therapeutics Incequities | $1,277,684 | – | 9,270 | +100.0% | 0.53% | – |
| New | Jasper Therapeutics Incequities | $905,000 | – | 500,000 | +100.0% | 0.37% | – | |
| BBIO | New | Bridgebio Pharma Incequities | $663,200 | – | 40,000 | +100.0% | 0.27% | – |
| TELA | New | Tela Bio Incequities | $575,581 | – | 54,096 | +100.0% | 0.24% | – |
| ALGS | New | Aligos Therapeutics Incequities | $552,269 | – | 631,887 | +100.0% | 0.23% | – |
| GLUE | New | Monte Rosa Therapeutics Incequities | $242,705 | – | 31,156 | +100.0% | 0.10% | – |
| New | Rocket Pharmaceuticals Incwarrants | $11,531 | – | 104,828 | +100.0% | 0.01% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- SilverArc Capital, LLC #1
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| INTRA-CELLULAR THERAPIES INC | 12 | Q3 2023 | 7.8% |
| IMMUNOGEN INC | 12 | Q3 2023 | 8.3% |
| Morphic Holding Inc | 12 | Q3 2023 | 4.5% |
| UNUM THERAPEUTICS INC | 12 | Q3 2023 | 3.2% |
| INSMED INC | 12 | Q3 2023 | 3.5% |
| UNITED THERAPEUTICS CORP DEL | 12 | Q3 2023 | 2.2% |
| MERUS N V | 11 | Q3 2023 | 5.1% |
| VERACYTE INC | 11 | Q3 2023 | 4.9% |
| EVOGENE LTD | 11 | Q3 2023 | 1.6% |
| COMPUGEN LTD | 11 | Q3 2023 | 1.1% |
View SILVERARC CAPITAL MANAGEMENT, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Benitec Biopharma Inc.Sold out | February 08, 2023 | 0 | 0.0% |
| DELCATH SYSTEMS, INC.Sold out | February 08, 2022 | 0 | 0.0% |
View SILVERARC CAPITAL MANAGEMENT, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| SC 13G/A | 2023-02-08 |
| 13F-HR | 2022-10-28 |
View SILVERARC CAPITAL MANAGEMENT, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.